SC
Soleus Capital Master Fund, L.P. disclosed a 8.7% stake in BBNX
Soleus Capital Master Fund, L.P. reported owning 8.7% of Beta Bionics, Inc. (BBNX) (4,828,619 shares) in a Schedule 13G filed Nov 9, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.